TransCode Therapeutics (RNAZ) said Sunday it has agreed to sell about 10.3 million shares of its common stock and warrants to purchase up to 10.3 million shares at a price of $0.98 per share and accompanying warrant for total expected gross proceeds of $10 million.
The warrants will be exercisable at a price of $0.86 per share.
Net proceeds will be used for product development activities, working capital and other general corporate purposes, the company said.
Closing of the offering is expected to occur Tuesday, subject to customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments